CandlesenseCandlesense
CYTKClinical Trials•globenewswire•

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

Sentiment:Positive (70)

Summary

(NASDAQ:CYTK) Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 30, 2025 by globenewswire

← Back to CYTK News
    Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine | CYTK Stock News | Candlesense